78 terminated. 78 Phase 2, 9 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 78 | Terminated 78 |
| Phase 1 | 9 | Terminated 9 |
| Phase 3 | 7 | Terminated 7 |
Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients MAP-Target Algorithm - Acute Kidney Injury, Cirrhosis | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 14 | 2024-02-01 | 2026-09-24 |
| A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Placebo, Avenciguat - Hypertension, Portal, Liver Cirrhosis | Phase 2 | Terminated | Boehringer Ingelheim | 22 | 2024-01-03 | 2025-06-12 |
| Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis PLN-74809, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Terminated | Pliant Therapeutics, Inc. | 320 | 2023-11-16 | 2026-08-05 |
| Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites | Phase 2 | Terminated | Genfit | 15 | 2023-07-02 | 2026-07-23 |
| Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) - Liver Cirrhosis | Phase 2 | Terminated | AstraZeneca | 205 | 2022-10-31 | 2026-09-25 |
| A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis HZN-825, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Terminated | Amgen | 153 | 2022-01-20 | 2025-12-03 |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant Durvalumab, Tremelimumab, Liver Transplant - Hepatocellular Carcinoma, Cirrhosis | Phase 2 | Terminated | University of Cincinnati | 8 | 2021-12-07 | 2026-05-06 |
| A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. APX-115, Placebo - COVID-19 | Phase 2 | Terminated | Aptabio Therapeutics, Inc. | 16 | 2021-10-20 | 2026-06-10 |
| The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Danazol, Placebo - Pulmonary Fibrosis, Telomere Shortening | Phase 2 | Terminated | The University of Queensland | 29 | 2021-09-07 | 2025-08-05 |
| Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy AXA1665, Placebo - Hepatic Encephalopathy | Phase 2 | Terminated | Axcella Health, Inc | 12 | 2021-06-29 | 2022-07-27 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Ixazomib - Systemic Sclerosis, Scleroderma | Phase 2 | Terminated | Michael M. Pham | 4 | 2021-04-28 | 2025-04-06 |
| Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy RBX7455, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver | Phase 2 | Terminated | Ochsner Health System | 5 | 2021-03-01 | 2023-10-03 |
| Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis Align Probiotic Supplement Capsule, Placebos - Fatty Liver Disease, Fibrosis, Liver | Phase 1 / Phase 2 | Terminated | Corewell Health East | 14 | 2021-01-12 | 2022-09-27 |
| LYT-100 in Post-acute COVID-19 Respiratory Disease LYT-100, Placebo - Covid19, Post-acute COVID-19 Respiratory Disease | Phase 2 | Terminated | PureTech | 185 | 2020-12-11 | 2026-06-23 |
| Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars PRP Injection, Saline Injection - Hypertrophic Scar | Phase 2 | Terminated | Vanderbilt University Medical Center | 3 | 2020-09-18 | 2023-01-09 |
| Losartan to Improve Hip Microfracture Losartan, Placebo - Hip Osteoarthritis, Hip Impingement Syndrome | Phase 1 / Phase 2 | Terminated | Steadman Philippon Research Institute | 1 | 2020-08-07 | 2023-10-30 |
| Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide. Ularitide, Placebo - Cirrhosis, Liver, Ascites Hepatic | Phase 2 | Terminated | University of Aarhus | 17 | 2020-08-01 | 2023-05-18 |
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis belapectin, Placebo - Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | Phase 2 / Phase 3 | Terminated | Galectin Therapeutics Inc. | 357 | 2020-06-25 | 2026-06-30 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
Showing 20 of 78. Sign in to see all of them.
Liver Cirrhosis (19) · Pulmonary Fibrosis (15) · Liver Cirrhosis, Biliary (12) · Idiopathic Pulmonary Fibrosis (9) · Hypertension, Portal (8) · Non-alcoholic Fatty Liver Disease (7) · Ascites (5) · Lung Diseases, Interstitial (5) · Carcinoma, Hepatocellular (4) · Cicatrix (4) · Hepatic Encephalopathy (4) · Keloid (4) · Liver Diseases (4) · Cicatrix, Hypertrophic (3)
Pathological Conditions, Signs and Symptoms (78) · Pathologic Processes (75) · Digestive System Diseases (43) · Liver Diseases (38) · Respiratory Tract Diseases (19) · Lung Diseases (18) · Bile Duct Diseases (13) · Biliary Tract Diseases (13) · Cholestasis (12) · Cholestasis, Intrahepatic (12) · Liver Cirrhosis (12) · Lung Diseases, Interstitial (12) · Skin and Connective Tissue Diseases (11) · Cicatrix (7)
simtuzumab (4) · Losartan (3) · Bosentan (2) · CC-90001 (2) · Danazol (2) · Sorafenib (2) · obeticholic acid (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 2-methyl-3-(2-((4-nitrooxybutyloxy)carbonyl)vinyl)phenyl ursodeoxycholic acid ester (1) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · 4-(9-(tetrahydrofuran-3-yl))-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylaminocyclohexan-1-ol (1) · Acetylcysteine (1) · Albumins (1) · Bevacizumab (1) · Bezafibrate (1)
Gilead Sciences (6) · Celgene (3) · Novartis Pharmaceuticals (3) · Genfit (2) · Intercept Pharmaceuticals (2) · Tirgan, Michael H., M.D. (2) · University of Padova (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Alicia Gerke (1) · Amgen (1) · Aptabio Therapeutics, Inc. (1) · Arena Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1)
United States (52) · United Kingdom (21) · France (16) · Germany (16) · Spain (16) · Canada (14) · Italy (12) · Australia (11) · Belgium (9) · Poland (9) · South Korea (8) · Netherlands (7) · Austria (5) · Japan (5) · Puerto Rico (5)
Michael H Tirgan, MD (2) · Alain Hendlisz, MD (1) · Alexander Meves, MD (1) · Alicia K Gerke, MD (1) · Andres Duarte-Rojo, M.D. (1) · Arena CT.gov Administrator (1) · Bhavisha Patel, M.D. (1) · Davendra Sohal, MD (1) · David A Shapiro, MD (1)
PMID 29990488, PMID 33307033, PMID 36750244, PMID 22383668, PMID 23499151, PMID 23664631, PMID 25500425, PMID 25543678, PMID 28818518, PMID 29486918, PMID 34504196, PMID 34857525, PMID 34894681, PMID 35058236, PMID 38484130, PMID 40692836, PMID 41807015
2016 (3), 2018 (2), 2023 (2), 2008 (1), 2009 (1), 2015 (1), 2019 (1), 2025 (1), R21DK092567 (1)